What question did this study set out to answer?

To evaluate the cost-effectiveness of nirsevimab compared to clesrovimab in preventing RSV-related diseases in infants in the U.S.

February 28, 2026Open Access

Cost-Effectiveness of Nirsevimab and Clesrovimab in Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Modeling Study

Key Points

To evaluate the cost-effectiveness of nirsevimab compared to clesrovimab in preventing RSV-related diseases in infants in the U.S.
Modeling study design to compare nirsevimab and clesrovimab
Sensitivity analyses to test robustness of findings
Assessment of healthcare utilization and costs
Nirsevimab is more cost-effective than clesrovimab
Nirsevimab offers greater clinical protection against RSV
Lower healthcare resource utilization associated with nirsevimab compared to clesrovimab

Abstract

Our findings predict that nirsevimab is economically dominant over clesrovimab while providing greater clinical protection against RSV-related disease in these scenarios. These results are robust to sensitivity analyses with nirsevimab consistently estimated as reducing healthcare resource utilization and total costs compared to clesrovimab across assumptions related to clesrovimab duration of cumulative efficacy as well as variation in key model parameters.

Bookmark

View Full Paper

Cite This Study

Yarnoff et al. (Thu,) studied this question.

synapsesocial.com/papers/69a287130a974eb0d3c02863 https://doi.org/https://doi.org/10.1007/s40121-026-01311-w

Bookmark

View Full Paper